Madison Asset Management LLC cut its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 15.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 82,140 shares of the healthcare product maker’s stock after selling 15,541 shares during the period. Madison Asset Management LLC’s holdings in Abbott Laboratories were worth $8,433,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in ABT. J. Stern & Co. LLP lifted its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Norges Bank purchased a new stake in Abbott Laboratories in the fourth quarter worth $2,938,892,000. Assenagon Asset Management S.A. raised its holdings in Abbott Laboratories by 303.0% in the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after purchasing an additional 3,330,368 shares in the last quarter. Ninety One UK Ltd purchased a new position in Abbott Laboratories during the fourth quarter valued at $336,815,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Analysts Set New Price Targets
ABT has been the topic of a number of recent research reports. Leerink Partners reduced their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Benchmark dropped their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. JPMorgan Chase & Co. raised their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $118.61.
Insider Buying and Selling
In other news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.
Abbott Laboratories Price Performance
Shares of NYSE:ABT opened at $99.67 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market cap of $173.61 billion, a price-to-earnings ratio of 32.26, a price-to-earnings-growth ratio of 2.03 and a beta of 0.61. The business has a 50-day simple moving average of $90.58 and a two-hundred day simple moving average of $101.66. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm posted $1.26 EPS. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.51 earnings per share for the current year.
Abbott Laboratories Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Stories
- Five stocks we like better than Abbott Laboratories
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
